Author: web Desk

February 21, 2023

• 1.81 billion lives improved by Philips’ health technology products, services and solutions
• Philips became the first health technology company to obtain approval by the Science Based Targets initiative (SBTi) for its entire value-chain CO₂ emissions reduction targets, including Scope 1-3
• Continued recognition for sustainability leadership – received CDP’s ‘A List’ rating for 10th year in a row
• Actively engaging with suppliers and customers to help reduce emissions across the end-to-end healthcare value chain
• With 77% renewable energy usage, Philips is well ahead of its 2025 goal
  

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has made strong progress towards realizing its key Environmental, Social, and Governance (ESG) ambitions. In 2022, Philips reached 1.81 billion people with its products and services, while further reducing operational emissions, and indirect (scope 3) emissions across the end-to-end healthcare value chain, together with its suppliers.

“We continue to move closer to our aim of improving 2 billion lives per year by 2025, while stepping up our sustainability efforts in our operations and value chain,” said Marnix van Ginneken, Chief ESG & Legal Officer at Royal Philips. “The growing momentum across the healthcare industry and among customers to reduce our collective environmental footprint encourages us on a daily basis as we continue to strive to reduce emissions across the end-to-end healthcare value chain and drive the shift to a circular economy.”

Increasing social impact
Illustrating the company’s increasing social impact, Philips’ health technology products, services and solutions improved 1.81 billion lives (1.67 billion in 2021), of which 202 million in underserved communities. This takes Philips closer to its goal of improving 2 billion lives per year by 2025, with 300 million in underserved communities. In 2022, improved access to care in underserved communities was driven by shared-value partnerships, the development of innovative digital solutions, and the roll-out of new business and financing models that are both sustainable and scalable.

Other key developments within the social dimension include a 30% representation of women in senior leadership roles, increased focus on employee health and well-being (both physical and mental health), and continued emphasis on ensuring a safe and healthy workplace.

Creating sustainable innovations
In 2022, the contribution from circular revenues increased to 18% of sales (2021: 16%). In 2022, Philips saw 10% more returns of large medical equipment compared to 2021 and closed the loop on more than 3,500 systems. Additionally, consumers started to make use of the newly introduced options to rent a Philips Avent breast pump or IPL Lumea hair removal device.

EcoDesigned products and solutions increased their revenue contribution to 71.7% (2021: 70.5%), supported by grooming and beauty products that contain over 25% recycled plastics and Oral Healthcare introducing its first brush heads containing 75% bio-based materials. Demand for sustainable healthcare systems is supported by the MR 5300 with its industry-leading BlueSeal magnet, helping radiology departments massively reduce the need for scarce helium gas.

Reducing operational emissions and waste
In addition to remaining carbon-neutral in its operations (since 2020), Philips achieved 77% (2021: 74%) renewable energy usage, exceeding the 75% goal for 2025. It also reduced transport- and distribution-related CO₂ emissions by 22% through a stricter air-freight policy and optimized warehouse locations.

Philips improved the circularity of its waste stream to 91% (2021: 87%), increasingly recycling, re-using or reducing waste. An example is the replacement of single use plastic in supplier packaging with boxes that can be used repeatedly. As a result, less than 0.1% of the remaining operational waste was land-filled, in line with our zero-waste to landfill ambition.

Philips is also proud that CDP, a global NGO that assesses the CO₂ emissions performance and management of reporting companies, ranked Philips on the CDP Climate Change ’A’ List for the 10^th time in a row, thanks to the company’s continued climate performance and transparency.

Advancing towards low-carbon operations and value chain
In 2022, Philips became the first health technology company with approval from the Science Based Targets initiative (SBTi) for its entire value-chain CO₂ emissions reduction targets, including Scope 1-3. In addition, 41% of suppliers (based on spend) have now committed to science-based targets (2021: 28%) – Philips’ goal is 50% by 2025.

Progressing in governance
Philips’ commitment to responsible and transparent governance is illustrated by the publication of the Philips Human Rights Report 2022, in which Philips updated stakeholders on its progress in addressing key human rights over the past year, along with plans for continuous improvement.

Philips continues to take an active role – in collaboration with global institutions such as the International Financial Reporting Standards (IFRS) Foundation, the World Economic Forum (WEF) and the European Union – to help drive the evolution towards a standard global ESG reporting framework.

For a full overview of Philips’ Environmental, Social, and Governance achievements, read chapter 5 of the Philips Annual Report 2022, which was published earlier today.

For further information, please contact:

Ben Zwirs
Philips Global Press Office
Tel.: +31 6 1521 3446
E-mail: ben.zwirs@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2022 sales of EUR 17.8 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments

• Philips MR5300 in use
• Refurbishment process

GlobeNewswire Distribution ID 1000783790

February 21, 2023

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today published its Annual Report 2022. Philips’ Annual Report 2022 will be on the agenda of the Annual General Meeting of Shareholders (AGM), to be held on May 9, 2023. The convocation notice and the agenda, including explanatory notes, for the AGM 2023 will be published in due course.

2022 was a very disappointing year for Philips and its stakeholders, and as recently announced, the company is taking firm action to strengthen patient safety and quality, improve its execution and step up performance with urgency in 2023.

The 2022 Remuneration Report, as included in the Annual Report 2022, will also be on the agenda of the AGM 2023. In his letter to Philips’ stakeholders, the Chairman of the Remuneration Committee explains that the Committee has been very mindful of the shareholder sentiment and the advisory vote regarding the 2021 Remuneration Report cast at the AGM 2022. The Remuneration Committee reports on how it reached out to the company’s shareholders immediately after the AGM 2022, and how the feedback received from shareholders in the second half of 2022 has been addressed.

The Remuneration Report furthermore explains how the remuneration in respect of the year 2022 has been impacted by Philips’ performance in 2022. In this context, and to further align with the company performance, as well as the sentiment and negative experience of the company’s shareholders and other stakeholders, the Supervisory Board and current Board of Management have jointly concluded that it was appropriate to waive any 2022 Annual Incentive (AI) pay-out and any vesting of the 2020 Long-term Incentive (LTI) grant of the members of the Board of Management.

Philips filed the Annual Report 2022 with the Netherlands Authority for the Financial Markets (AFM) in European Single Electronic Format (ESEF) and expects to file the report on Form 20-F with the U.S. Securities and Exchange Commission later today (www.sec.gov).

The Annual Report 2022 (in ESEF and on Form 20-F) is available to shareholders and other interested parties at www.results.philips.com. A printed copy can be obtained free of charge upon written request to the following email address: annual.report@philips.com.

For further information, please contact:

Ben Zwirs
Philips Global Press Office
Tel.: +31 6 1521 3446
E-mail: ben.zwirs@philips.com

Derya Guzel
Philips Investor Relations
Tel.: +31 20 59 77055
E-mail: derya.guzel@philips.com

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2022 sales of EUR 17.8 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Forward-looking statements

This release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips’ organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.

GlobeNewswire Distribution ID 1000783787

SHANGHAI, China, Feb. 20, 2023 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) today announced that the pre-specified interim analysis has been completed for a randomized, double-blind, placebo-controlled, multi-center phase III clinical study (“TORCHLIGHT Study”, NCT04085276) examining the company’s product toripalimab in combination with paclitaxel for injection (albumin-bound) in patients with an initial diagnosis of stage IV or recurrent/metastatic triple-negative breast cancer. The Independent Data Monitoring Committee (IDMC) has determined that the primary endpoint met the pre-defined efficacy boundary. Junshi Biosciences will communicate with the regulatory authorities regarding matters related to the supplemental new drug application in the near future.

According to GLOBOCAN 2020, breast cancer had the highest incidence rates worldwide, with 2.26 million new cases and 0.68 million deaths in 2020. In China, 0.42 million new cases and 0.12 million deaths due to breast cancer were reported in 2020, accounting for 18.4% and 17.1% of global cases, respectively. Amongst these breast cancer cases, triple-negative breast cancer (“TNBC”) accounted for approximately 15% to 20% of them. TNBC is a more aggressive type of tumor with a higher risk of recurrence and poor prognosis. Advanced TNBC is insensitive to targeted therapy and endocrine therapy, and there are currently no specific treatment methods available.

In recent years, oncology immunotherapy drugs represented by PD-(L)1 inhibitors have achieved a series of breakthroughs in treating various types of tumors. However, to this day, no immunotherapy drugs have been approved for advanced TNBC in China, and chemotherapy remains the primary treatment option. Alternative drugs include anthracyclines, taxanes, platinum-based drugs, etc. Both mono-chemotherapy and combined chemotherapy have poor efficacy, with a median survival time of about nine to 12 months and a 5-year survival rate of less than 30%.

The TORCHLIGHT study is the first Phase III registration study in China to achieve a positive outcome in an advanced triple-negative breast cancer immunotherapy. This randomized, double-blind, placebo-controlled, multi-center Phase III clinical study was designed to compare the safety and efficacy of toripalimab combined with paclitaxel for injection (albumin-bound) and placebo combined with paclitaxel for injection (albumin-bound) in patients with an initial diagnosis of stage IV breast cancer or recurrent/metastatic triple-negative breast cancer.

The interim analysis of this study demonstrated that, compared with paclitaxel for injection (albumin-bound), toripalimab in combination with paclitaxel for injection (albumin-bound) in patients with initial diagnosis of stage IV or recurrent metastatic triple-negative breast cancer can significantly prolong the progression-free survival (PFS) of PD-L1 positive patients. Meanwhile, the overall survival (OS), one of the secondary endpoints, also showed a clear trend of improvement in PD-1 positive patients as well as in all patients regardless of PD-1 status. The safety data of toripalimab is consistent with known risks, and no new safety signals were identified.

“The TNBC subtype of breast cancer is the most aggressive and has the worst prognosis,” said Professor Zefei JIANG from the Department of Oncology at the Chinese People’s Liberation Army General Hospital, the Vice President and Secretary General of the Chinese Society of Clinical Oncology (CSCO) and Principal Investigator of the TORCHLIGHT study. “Advanced TNBC patients have limited survival rates and lack effective treatment methods. Aiming to improve patient survival, a group of Chinese researchers successfully conducted the first phase III study on immune-oncology for advanced TNBC patients, even amidst the COVID-19 pandemic, and achieved breakthrough results. These results demonstrate that the combined use of the monoclonal antibody, toripalimab, with traditional chemotherapy significantly prolonged the PFS of patients, and this has the potential to become a new standard treatment for patients with an initial diagnosis of stage IV TNBC as well as those with recurrent/metastatic TNBC, offering patients new hope!”

“I’m extremely pleased that TORCHLIGHT research has been successful, and its success is a result of the dedicated efforts of patients, researchers, and development teams,” said Dr. Jianjun ZOU, the President of Global Research and Development at Junshi Biosciences. “We will work closely with regulatory authorities to ensure that relevant indications are approved as soon as possible. We hope that toripalimab will provide better treatment options for patients and address unmet medical needs.”

About Toripalimab

Toripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function). Blocking PD-1 interactions with PD-L1 and PD-L2 promotes the immune system’s ability to attack and kill tumor cells.

More than thirty company-sponsored toripalimab clinical studies covering more than fifteen indications have been conducted globally by Junshi Biosciences, including in China, the United States, Southeast Asia, and European countries. Ongoing or completed pivotal clinical trials evaluating the safety and efficacy of toripalimab cover a broad range of tumor types including cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney and skin.

In China, toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing (approved in China as TUOYI®). Currently, there are six approved indications for toripalimab in China:

1. unresectable or metastatic melanoma after failure of standard systemic therapy;
2. recurrent or metastatic NPC after failure of at least two lines of prior systemic therapy;
3. locally advanced or metastatic urothelial carcinoma that failed platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy;
4. in combination with cisplatin and gemcitabine as the first-line treatment for patients with locally recurrent or metastatic NPC;
5. in combination with paclitaxel and cisplatin in first-line treatment of patients with unresectable locally advanced/recurrent or distant metastatic esophageal squamous cell carcinoma (“ESCC”);
6. in combination with pemetrexed and platinum as the first-line treatment in EGFR mutation-negative and ALK mutation-negative, unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer (“NSCLC”).

The first three indications have been included in the National Reimbursement Drug List (NRDL) (2022 Edition). Toripalimab is the only anti-PD-1 monoclonal antibody included in the NRDL for treatment of melanoma.

In terms of international layout, the Biologics License Application (BLA) for toripalimab in combination with gemcitabine/cisplatin, for the first-line treatment of patients with advanced recurrent or metastatic NPC and toripalimab monotherapy for the second-line or later treatment of recurrent or metastatic NPC after platinum-containing chemotherapy is under review by the U.S. Food and Drug Administration (FDA). In December 2022 and February 2023, the European Medicines Agency (EMA) and the Medicines and Healthcare Products Regulatory Agency (MHRA) accepted the marketing authorization application (MAA) for toripalimab in combination with cisplatin and gemcitabine for the first-line treatment of patients with locally recurrent or metastatic NPC, and toripalimab in combination with paclitaxel and cisplatin for the first-line treatment of patients with unresectable locally advanced/recurrent or metastatic esophageal squamous cell carcinoma, respectively.

About Junshi Biosciences
Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA monoclonal antibody for the treatment of various cancers was the first in the world to be approved for clinical trials by the FDA and NMPA and has since entered Phase Ib/II trials in both China and the US. Its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA.

In the face of the pandemic, Junshi Biosciences’ response was strong and immediate, joining forces with Chinese and international scientific research institutions and enterprises to develop an arsenal of drug candidates to combat COVID-19, taking the initiative to shoulder the social responsibility of Chinese pharmaceutical companies by prioritizing and accelerating COVID-19 R&D. Among the many drug candidates is JS016 (etesevimab), China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2 and the result of the combined efforts of Junshi Biosciences, the Institute of Microbiology of the Chinese Academy of Science and Lilly. JS016 administered with bamlanivimab has been granted Emergency Use Authorizations (EUA) in over 15 countries and regions worldwide. As of December 3 2021, over 700,000 patients have been treated with bamlanivimab or bamlanivimab and etesevimab, potentially preventing more than 35,000 hospitalizations and at least 14,000 deaths. Meanwhile, VV116, a new oral nucleoside analog anti-SARS-CoV-2 drug designed to hinder virus replication, has been approved for marketing in China and Uzbekistan. The JS016 and VV116 programs are a part of the company’s continuous innovation for disease control and prevention of the global pandemic.

Junshi Biosciences has more than 3,100 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc). For more information, please visit: http://junshipharma.com.

Junshi Biosciences Contact Information
IR Team:
Junshi Biosciences
info@junshipharma.com
+ 86 021-6105 8800

PR Team:
Junshi Biosciences
Zhi Li
zhi_li@junshipharma.com
+ 86 021-6105 8800

GlobeNewswire Distribution ID 8753126

LONDON, Feb. 20, 2023 (GLOBE NEWSWIRE) — Following the successful completion of seed and private rounds and 9 figures trading volumes on their copy trading platform, Mizar (MZR Inc) is excited to announce its upcoming Token Generation Event, on 9th March 2023.

Since the open Beta release, Mizar has been striving to bring a token to make crypto trading easier for everyone. Having completed all major milestones in their project roadmap, the team is now moving towards the next step – rolling out an unprecedented, subscription-free social trading platform.

Cino Gerard, COO, is confident about the team’s capabilities and sees a bright future.

“What I love about Mizar is the community. We have been diligently building this product together with many of our users who helped us craft the roadmap, refine the product, and deliver something that people use, every day. That’s what brought us more than ten thousand users a few months after releasing the open Beta.”

Francesco Ciuci, CEO, is excited to announce the upcoming event.

“Our goal is to make Mizar the most powerful social trading platform, providing an amazing set of tools for traders to manage their assets and enabling them to share their trading strategies with the Mizar community. The TGE is an important milestone for all of us and our users are waiting for this for a couple of months now!”

Talking about the MZR Token, he added:

“The MZR Token provides various benefits to both users and investors, such as fees reduction up to 95% and strong token economics, enabling users to generate passive income and contribute to the platform’s progress and expansion.”

Mizar is approaching the conclusion of its CeFi Roadmap Phase, which focuses on developing all trading services on Centralized Exchanges like Binance. After completion, Mizar will enter its DeFi Phase, expanding its services to Decentralized Exchanges, and adding analytics and Machine Learning to support traders to make well-informed decisions.

About Mizar

With over 10,000 users trading millions in volume daily, Mizar is the choice for those who demand the best when trading crypto. Say goodbye to FOMO and missed opportunities, and embrace hands-free trading on your favorite CEX and DEX with advanced bots and smart tools. Share your bots with others on the best social trading platform in the crypto world and earn a passive income.

Photo: https://www.globenewswire.com/NewsRoom/AttachmentNg/2896a32c-4e7f-415f-b7f0-cdc0c5b7d4ff

Media Contact:
hello@mizar.com

GlobeNewswire Distribution ID 8752989

Winners will be announced in April

NEW YORK, Feb. 20, 2023 (GLOBE NEWSWIRE) — Network for Teaching Entrepreneurship (NFTE) selected the top finalists in its World Series of Innovation (WSI), presented by Citi Foundation.

Finalists represent the top 10 teams in each of WSI’s 10 challenge categories. WSI encourages entrepreneurship and innovation in youth ages 13 to 24, prompting them to solve global challenges in alignment with the UN Sustainable Development Goals, including climate change, environmental degradation and poverty.

There were 1,249 total submissions from 59 countries around the world. WSI invited participants to submit innovative solutions to unique challenges supported by Citi Foundation, Bank of the West, EY, Mary Kay, Mastercard, Maxar, MetLife Foundation, Link Logistics, ServiceNow, and Zuora. Each challenge’s first-, second-, and third-place teams will be announced in April. Prizes range from $300-$1,500.

By keeping this competition free and accessible for youth worldwide, NFTE upholds its vision of increasing equity in education for youth, regardless of their background.

“Our World Series of Innovation embodies what NFTE teaches every day in our classrooms and communities,” said Dr. J.D. LaRock, President and CEO of NFTE. “By promoting an entrepreneurial mindset and a passion for advancing equity in society, WSI is proof of the power of our youth to create meaningful change. We were blown away by our participants this year and their ability to think critically and uniquely about some of the biggest challenges we face today, including environmental, economic, social and racial injustice. Innovation is critical for the development and betterment of our world and is an act of hope for a better future for the planet and generations to come.”

Finalists represent Bangladesh, Canada, India, Mexico, Republic of Korea, Rwanda, Singapore, Taiwan, Thailand, Trinidad and Tobago, United Kingdom, Vietnam, and the United States (including California, Connecticut, the District of Columbia, Florida, Georgia, Hawaii, Minnesota, Missouri, New Hampshire, New Jersey, Pennsylvania, Texas, and Virginia).

Among the ideas are Aqua Made, a U.S. team’s concept for decreasing the amount of household water usage by connecting faucets to a digital app; DyCon from Bangladesh, which tackles the large carbon footprint produced by cotton dyeing companies; and EduMaster from India, which aims to increase financial literacy rates in women by creating easily accessible, digital resources. Other projects include Sea Saver, an American team’s proposed product to remove oil from the ocean; Trinidad and Tobago’s Seaweed Solutions, which recycles seaweed to create sustainable material for construction; and Thailand’s Soilmate, a composting bin to decrease waste.

NFTE motivates youth to ignite their entrepreneurial mindset by thinking about real-world challenges. Doing so empowers future leaders outside of a traditional educational curriculum.

To learn more, visit nfte.com. Find a video about the WSI finalists at innovation.nfte.com. Direct media inquiries, including requests regarding the teams and their ideas, to Cecilia Apodaca at 970-237-0440 or cecilia@thetascgroup.com; or Denise Berkhalter at 917-281-4362 or marketing@nfte.com.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/df72e287-a689-44da-a57b-5a8bf2617e2d

GlobeNewswire Distribution ID 8752140

Global Telephony Provider Webtel.mobi and its US Subsidiary WM Holdings Inc. issue joint clarification highlighting their independent and nonaligned postures, as well as the differences between Webtel.mobi’s TUV Digital Currency equivalent and Cryptocurrencies

LONDON and NEW YORK, Feb. 20, 2023 (GLOBE NEWSWIRE) — The global Cryptocurrency sector is currently undergoing unstable transitionary events. These include bankruptcies and failures of large entities, regulatory action being taken or contemplated within that sector by regulatory authorities, and adversarial postures being taken up by Stakeholders against Cryptocurrency Asset Managing firms.

Against this backdrop – and following contact established with it by entities involved in some of these unstable / adversarial events – Webtel.mobi (Holdings) Limited and its US Subsidiary WM Holdings Inc. have issued a public clarification – to and for the various parties contacting it, and all/any other relevant parties – clarifying their position and stance in this situation, as well as the structure and nature of the TUV Digital Currency / CBDC equivalent.

Firstly, as a clarification of the status and designation of the TUV Digital Currency / CBDC equivalent, it is not classified as a Cryptocurrency or a Stablecoin. This is because:

• Although the TUV indeed possesses every positive characteristic of Cryptocurrencies, Stablecoins, Digital Currencies – and all the required characteristics of proposed Wholesale and Retail CBDCs on a Global Multicurrency basis – it also exhibits the following very important differences between it and Cryptocurrencies / Stablecoins:
• TUVs are not sold as Retail Speculative Commodities at costs in the tens of thousands of dollars per TUV. They are provided and acquired at zero cost. Their varying Face Values are determined by the Acquirer, who converts the Currency amount of choice into TUV Digital Currency.
• The Face Value of each Currency-Backed “Standard TUV” is permanently backed by 100% of the Currency of the TUV Face Value, permanently stored in a Regulated Bank Account (i.e. it is a 100% Reserve Currency equivalent).
• The Face Value of each Gold-Backed “Secured TUV” is permanently backed by 100% of the TUV Face Value in Gold Bullion, permanently stored in a Secured Gold Storage Facility (i.e. it is a Gold Standard Currency equivalent).
• The Face-Value of each Programmable “Smart TUV” is permanently backed by either 100% of the Face value in either Currency or Gold (i.e. because Standard TUVs or Secured TUVs are used as the baseline Programmable Instrument).
• The Securing Currency or Securing Gold of any TUV is permanently available for redemption – on demand by the owner – to the Bank Account of the owner and/or the possession of the owner (if Gold).
• The TUV Backing Currency can be converted to all other International Reserve Currencies – and other currencies – on demand and without limitation as to the number of conversions, by the owner.
• The TUVs function according to Distributed Ledger+ and Blockchain+ Systems – meaning that the asset is recoverable by the owner even in a case of Private Keys being lost or misplaced; and that loss or theft of the asset is not possible.
• The Webtel.mobi Platform and System reside and function within a Unitary Global System, in which all aspects of Global TUV Creation, Distribution, Acquisition, Purchase or Sale or Trade or Exchange Transactions, Transfer + Payment Transactions, Settlement and Redemption are carried out from, and on, one Platform. This removes all intermediary layers and fees.
• A TUV Solution facilitating all aspects of TUV activity and transactions exists for the Global Unbanked population exists, facilitating entry of all Unbanked or Underbanked persons Globally into the 21^st Century Global Digital Economy environment.
• The Webtel.mobi System and TUVs are not in a regulatorily disputed or regulatorily grey-area sector. They are firmly in the Telephony Sector, and have been due diligenced over 13 years in 60+ Due Diligences. The most recent satisfactorily Regulatory Review by the Senior Telephony Regulator in Guernsey – the Guernsey Competition and Regulatory Authority – was in late 2022 (on top of a previous unambiguous clarification by the Guernsey Financial Services Commission in 2021 that Webtel.mobi is not in the Financial Services Sector). See the document “Recent Regulator’s Review” in the “Resources” section of this article.

WM’s TUVs can be used for large or small transactions in many varying currencies

The Webtel.mobi TUVs and the entire TUV System were reviewed for over a year by some of the world’s foremost Macroeconomists and one of the world’s foremost Macroeconomic Entities. An entire Research Paper was published on the TUVs that confirms all of its characteristics, and that confirms the substantial differences between the TUVs and Cryptocurrencies / Stablecoins, as well as the TUVs’ other ubiquitous and Strategic global applications (See the Research Paper “New Dimensions for the TUV in the Webtel.mobi System” in the “Resources” section of this article).

For this reason, it is not only entities that currently have holdings in the Grayscale Bitcoin Trust that are interested to use TUVs and other Webtel.mobi facilities / the Webtel.mobi Platform.

Multiple other entities unconnected to the Cryptocurrency sector events are also considering establishing their own Vehicles through which to acquire TUVs in multiple currencies – or Gold-Backed Secured TUVs – for their clients, for their discretionary portfolios, or for their own portfolios. This is particularly given the proven Inflation and Currency Depreciation Hedges that the TUVs provide. (See the document “TUVs as an Inflation and Currency Depreciation Hedge” in the “Resources” Section of this article).

Moreover, although the Global Cryptocurrency-related Sector represents a significant Market Sector in terms of both value and volume, it is only considered a Market of Secondary Interest to Webtel.mobi. This is because the Cryptocurrency-related Sector – as significant as it is – is small in volume and value compared to the other market sectors in which Webtel.mobi’s TUVs, Facilities and Platform currently have proven command leads.

These include:

• Being a proven and operational Global Alternative to SWIFT for Transfers
• Being a proven and operational Alternative to the Global FX Market for Conversions
• Being a proven and operational Alternative to the Global Payments Sector for Online and Offline Payments
• Being a proven and operational Alternative to Global Clearing Houses for Settlements
• Being a proven and operational Global Wholesale and Retail CBDC equivalent
• Being a proven and operational Global Unitary Currency equivalent
• Other Globally Ultra-High Value Attributes

(See the Research Paper “Money and Credit: Potential Expansion of the WM System” in the Webtel.mobi System” in the “Resources” section of this article).

It is as a result of these Command Leads in these Ultra-High Value Global Sectors that the personnel of Central Banks have previously requested internships at Webtel.mobi. Moreover, an entity representing all Central Banks engaged in CBDC / Digital Currency Research previously requested Webtel.mobi to set up a joint project to share its knowledge with them, due to it having its own completed, proven and fully-operational Global CBDC-equivalent.

Currently, it has been widely reported in the media that that the SEC is involved in investigations with regard to some of Digital Currency Group’s (“DCG”) subsidiary Genesis Global’s activities and/or transactions. Simultaneously, DCG’s subsidiary Grayscale Investments is reportedly litigating against the SEC in an effort to gain EFT status for the Grayscale Bitcoin Trust.

These events narrowly precede – or follow closely on the heels of – the SEC’s reported increasing crackdown on aspects of Cryptocurrency trading in general, and the fallout from the collapse of the Cryptocurrency-based entity FTX and its subsidiary Alameda Research.

Moreover, it has recently also been widely reported that a number of Stakeholders in the world’s largest Bitcoin and Cryptocurrency Asset Manager – the Grayscale Bitcoin Trust (“GBTC”) – have commenced litigation or activism against GBTC. These include well-known firms such as ARK Investment Management, UTXO Management, Fir Tree Partners, Osprey Fund and Valkyrie.

In this unstable environment and climate in that sector, some of the Stakeholder entities involved in the dispute and/or litigation with GBTC have contacted Webtel.mobi, inquiring as to the potential for them to diversify their holdings in that entity by establishing vehicles that hold TUVs as opposed to GBTC and/or Bitcoin and/or other Cryptocurrency holdings.

Webtel.mobi and its US Subsidiary WM Holdings Inc. have consequently corresponded with the larger of the relevant entities engaged in these adversarial activities – and with also with the Digital Currency Group and the Grayscale Bitcoin Trust – to clarify Webtel.mobi’s and WM Holdings Inc.’s position.

The reasons for this are that:

• Webtel.mobi’s US Subsidiary – WM Holdings Inc. – is in the final stages of preparation to commence its Regulation D Rule 506(c) Private Placement, and is currently sourcing potential Placement Partner entities and expressions of potential interest from verified Accredited Investors, directly and via its website.
• Webtel.mobi is preparing for Recommencement of Unrestricted Global Operations upon conclusion of WM Holdings Inc.’s Private Placement.

Consequently, it is important to both Webtel.mobi and WM Holdings Inc. to clarify their positions, so as to remain separate from any adversarial interactions by any parties against each other.

As such – and as Webtel.mobi and WM Holdings Inc. have informed all relevant parties in writing – the following clarification is applicable:

• Webtel.mobi (Holdings) Limited (“WMHL”) and WM Holdings Inc. (“WMHI”) are entities that are 100% shareholder-owned, and are independent of corporate ownership, or affiliation with any other entity or entities.
• WMHL and WMHI do not and will not make any public comment – whether negative, positive or descriptive – regarding any other entity or entities, product, facilities or sectors; or enjoin in any actions by any parties against any other parties; publicly or privately.
• Any appropriately KYC’d entity or person – whether DCG, GBTC, entities that are stakeholders in any of those entities, or unrelated to any of those entities – may, at their own discretion and after their own appropriate due diligence, freely acquire Webtel.mobi TUVs, for their own personal or corporate portfolios or vehicles, with or without corporate interaction with WMHL or WMHI. All that is required is to join as a Member on the WMHL Platform or a Platform of any WMHL “VSMP” (Affiliate) in WMHL’s “TMG Global Alliance”.

In summary, neither WMHL nor WMHI will become involved with, nor make any statements regarding, nor in any way enjoin in any adversarial interactions with or against, any other party or parties.

WMHL and WMHI have their own well-planned and well-functioning agendas and timelines, which are proceeding smoothly. Their only interest at this time – and for the future – is the successful implementation and conclusion of WMHI’s Private Placement, and thereafter the successful Global Implementation of WMHL’s Recommencement of Global Operations.

Resources

Website of WM Holdings Inc.:
https://wmholdings.mobi

Website of Webtel.mobi (Holdings) Limited:
https://webtel.mobi/pc/

Research Paper “New Dimensions for the TUV in the Webtel.mobi System”:
https://webtel.mobi/media/info/new-dimensions-for-the-tuv-in-the-webtelmobi-system.pdf

Research Paper “Money and Credit: Potential Expansion of the WM System”:
https://webtel.mobi/media/info/money-and-credit-potential-expansion-of-the-wm-system-april-2021.pdf

Research Paper “Another Breton Woods Reform Moment: Let Us Look Seriously at the Clearing System”
https://webtel.mobi/media/info/another-bretton-woods-reform-moment-let-us-look-seriously-at-the-clearing-union.pdf

“TUVs as an Inflation and Currency Depreciation Hedge” Document:
https://webtel.mobi/media/info/webtel-mobi-tuvs-as-a-hedge-to-protect-against-currency-depreciation-and-inflation.pdf

“Recent Regulator’s Review of WMHL” Document:
https://webtel.mobi/media/info/22-12-07-confirmation-letter-regarding-the-gcra-review-of-wmhl.pdf

Video detailing Research on the Webtel.mobi System:
https://www.youtube.com/watch?v=XYBrCikUhn8

International Article on the Webtel.mobi System:
https://webtel.mobi/media/info/digital-currencies-and-instability-in-the-international-financial-system.pdf

“The TEL.mobi Group Global Alliance” Page:
https://webtel.mobi/pc/info/tmg-global-alliance/

Contact:
wm@thoburns.com

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/05c904c2-b22d-4eca-a035-161a191d8a8a

https://www.globenewswire.com/NewsRoom/AttachmentNg/adfacaec-0428-412b-b012-efb5ddd8d9ce

Photos are also available at Newscom, www.newscom.com, and via AP PhotoExpress.

 GlobeNewswire Distribution ID 8752632

DUBLIN, Feb. 20, 2023 (GLOBE NEWSWIRE) — Innovation Zed, an Irish R&D company specialising in the design, development and manufacturing of medical technologies, announced today it has secured a CE Mark for the InsulCheck DOSE add-on device. As a leader in connected and smart drug delivery technologies, this certification showcases our commitment to meeting relevant health, safety, and environmental requirements regarding consumer safety in the European Union (EU). It also opens the door for commercial expansion within Europe for the growing company.

InsulCheck DOSE is a single-unit add-on device for pen injectors that automatically captures dose value dialled, injection event time stamp and temperature as well as mounting and unmounting events. With InsulCheck DOSE, real-time injection event data are logged and sent automatically to a compatible display device. Product highlights include:

• A discreet add-on device compatible with all pen-injectors
• Captures dose dialled, timestamp, ambient temperature, etc.
• A convenient device with no buttons, no calibration requirements or interference with the normal injection process
• Increased user engagement through high-quality usability support features from a vibrant OLED screen

Innovation Zed is dedicated to helping insulin pen users within the diabetes population. Given our understanding of the challenges faced by insulin pen users worldwide, our focus is to support all insulin pen users regardless of their injection pen of choice. As a result of a collaboration with our partner SHL Medical and its subsidiary SHL Technologies, InsulCheck DOSE has been developed to meet the compatibility challenges presented by various injection pen designs and in particular the difficulties in working on a technology to reliably and accurately support low-cost disposable pens.

Dr Dean Minnock, CEO of Innovation Zed, said, “InsulCheck DOSE is a third-generation product of the InsulCheck family and the most intelligent and compatible evolution of the InsulCheck platform. InsulCheck DOSE provides data that, when applied correctly, facilitates an evidence-driven approach to precision insulin management and significantly helps people with diabetes make more informed choices for their personal therapy plan. Our InsulCheck DOSE supports all insulin pens without changing the usability of the pen in any way and without interfering in the normal injection process. In securing the CE mark for InsulCheck DOSE we reached an incredible milestone for our company and for people living with diabetes in Europe.”

Innovation Zed expects to initiate a commercial launch of InsulCheck DOSE in Europe during 2023. The company also has plans to introduce bespoke variations of InsulCheck DOSE to new injection devices for various drug therapies over the coming years.

About Innovation Zed

Innovation Zed, Ltd. empowers people to take control of diabetes through connected technology for insulin injection pens. Headquartered in Dublin, Ireland, Innovation Zed has emerged as a leader in injection pen technology. By listening to the needs of users, caregivers, and providers, Innovation Zed simplifies and improves diabetes management around the world. For more information about InsulCheck DOSE visit www.innovationzed.com.

Contact Information:
Andrew Fitzpatrick
Research and Innovations Manager
andrewf@innovationzed.com

Dean Minnock
CEO
deanm@innovationzed.com

Related Images

Image 1: InsulCheck DOSE by Innovation Zed

InsulCheck DOSE automatically captures dose dialled and time since last injection

This content was issued through the press release distribution service at Newswire.com.

Attachment

• InsulCheck DOSE by Innovation Zed

GlobeNewswire Distribution ID 8752354